Get the industry's most important news delivered every morning. Trusted by professionals at Pfizer, Moderna, and Mayo Clinic.
Free forever. Unsubscribe anytime. No spam.
Want deeper analysis? Check out our premium tier.
Everything you need to stay ahead in biotech, delivered in 5 minutes every morning.
Key deals, clinical milestones, regulatory updates, and funding rounds. No fluff—just the signal you need to start your day informed.
Track emerging companies before they break out. We cover Series A/B rounds, preclinical breakthroughs, and founder movements others miss.
Enrollment trends, site activation updates, FDA decisions, and patient recruitment insights that impact your trials and investments.
Curated intelligence from a team with 15+ years of biotech journalism experience. We filter out the noise so you get only what matters. Free tier gives you everything you need to stay informed.
From bench scientists to C-suite executives, BioMed Nexus is the daily habit for biotech professionals.
Not all biotech newsletters are created equal. Here's how we compare.
Everything you need to know about the best biotech newsletter.
Join 95,000+ biotech professionals who trust BioMed Nexus for their daily industry intelligence.
Free forever. Unsubscribe anytime. No spam.
Want deeper analysis? Check out our premium tier.
Breakthroughs, pipelines, data drops, and deals shaping the biotech landscape.
The science works. The manufacturing doesn’t scale. That is the central tension in cell and gene therapy right now. More than 3,000 cell and gene therapy clinical trials are active worldwide. Over two dozen CGT products have received regulatory approval. And nearly $15 billion flowed
More than 200 AI-designed drugs are now in clinical development. Phase I success rates for AI-discovered compounds are running between 80% and 90%, roughly double the historical average. The first fully AI-designed drug has posted positive Phase IIa efficacy data in humans. And in the
Every breakthrough drug has an invisible army behind it. Not just the scientists in lab coats or the executives signing deals — but the platforms, tools, and service companies that form the infrastructure of modern drug development. From the AI systems designing molecules to the
What Is a Biomarker: Modern medicine runs on measurement. Before treating a disease, you need to detect it. Before knowing if a drug works, you need to track its effects. Before predicting who will respond to therapy, you need signals that distinguish responders from non-responders.
BioMed Nexus delivers a fast, daily industry briefing for leaders across biotech, medtech, and pharma. Every weekday morning, we curate the most important developments, high-signal insights, and need-to-know updates so you can stay informed, move quickly, and make confident decisions in a rapidly evolving landscape.
